Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by August 25, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the availability of weight-loss drug Wegovy for Hims subscribers [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the Court by August 25, 2025, to represent other class members [2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the access to compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [4]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged securities fraud related to misleading statements about its collaboration with Novo Nordisk and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations of the Lawsuit - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - It is alleged that the company failed to disclose the risks associated with its collaboration with Novo Nordisk, leading to a significant risk of termination of the partnership [2] - Novo Nordisk officially terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason, resulting in a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5] - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [5]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [2] - It is alleged that this situation posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Berger Montague is investigating potential securities fraud claims against Hims & Hers Health Inc. following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and regulatory non-compliance [1][3][4]. Group 1: Legal Investigation - Investors who acquired Hims & Hers securities between April 29, 2025, and June 22, 2025, have until August 25, 2025, to seek appointment as lead plaintiff representative [2]. - The lawsuit claims that Hims & Hers made materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk [4]. Group 2: Market Reaction - Following the announcement of the partnership termination, Hims & Hers shares fell by over 34% in intraday trading, indicating significant investor concern over regulatory compliance and reputational risks [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by August 25, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings available to its subscribers [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint states that Hims failed to disclose that its communication with Novo Nordisk would not ensure a long-term collaboration for access to Wegovy for its subscribers [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk and the availability of branded Wegovy alongside these options [4]. - Defendants are accused of making misleading statements about the partnership with Novo and the ongoing access to Wegovy for Hims users [4].

Core Narrative - The healthcare sector is experiencing a decline, presenting potential investment opportunities for those willing to take on individual stock risks, particularly with the rise of Ozempic, a weight loss treatment that has gained significant traction in American households [1][2]. Group 1: Investment Opportunities - Companies like Hims & Hers Health Inc. and Eli Lilly and Co. are positioned to benefit from the Ozempic trend, with Hims & Hers focusing on a subscription model that provides stable growth and downside protection [4][10]. - The Health Care Select Sector SPDR Fund offers a diversified investment approach for those hesitant to invest in individual stocks, showing a performance gap of approximately 26% compared to the S&P 500 [6][7]. Group 2: Company Analysis - Hims & Hers Health - Hims & Hers has a gross profit margin of 76.2%, comparable to software companies, and is viewed positively by some institutions, including Nomura Holdings, which invested $8 million [11][12]. - The stock is currently priced at $43.48, with a price target of $38.92, indicating potential for growth despite being primarily associated with weight loss [8][9]. Group 3: Company Analysis - Eli Lilly - Eli Lilly has a market capitalization of $663 billion, providing it with the resources to scale effectively in the competitive landscape of weight loss products [13]. - Analysts have a consensus view of a Moderate Buy for Eli Lilly, with a price target of $950.17, suggesting a potential rally of 35.8% from its current trading price [14][15].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. spans from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements made by the defendants about the company's business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over- the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleadin ...